Pembrolizumab Improves DFS Without Compromising HRQOL in High-Risk Muscle-Invasive Urothelial Carcinoma
Clinical Summary:
- Design/Population: Phase 3 AMBASSADOR trial assessing health-related quality of life in 560 patients with high-risk muscle-invasive urothelial carcinoma randomized to adjuvant pembrolizumab or observation after radical surgery.
- Key Outcomes: At 12 months, no statistically significant or clinically meaningful differences in patient-reported outcomes were observed between treatment arms across EQ-5D-5L, EORTC QLQ-C30, and BLM30 measures.
- Clinical Relevance: These findings indicate that the disease-free survival benefit of adjuvant pembrolizumab is achieved without compromising health-related quality of life, further supporting its use in the adjuvant setting.
Ronald Chen, MD, University of Kansas Medical Center, Kansas City, Kansas, reviews results from the AMBASSADOR trial evaluating health-related quality of life (HRQOL) in patients with high-risk muscle-invasive urothelial carcinoma receiving adjuvant pembrolizumab after radical surgery.
While pembrolizumab previously demonstrated a significant improvement in disease-free survival compared with observation, patient-reported outcomes at 12 months showed no statistically significant or clinically meaningful differences between treatment arms across multiple HRQOL measures.
These findings, presented at the 2026 ASCO Annual Meeting in Chicago, Illinois, suggest that adjuvant pembrolizumab can improve clinical outcomes without compromising quality of life, further supporting its use in this patient population.
Source:
Chen RC, Dueck AC, Fruth B, et al. Health-related quality of life (HRQOL) with pembrolizumab or observation for high-risk muscle-invasive urothelial carcinoma after surgery: Results from the AMBASSADOR randomized trial (Alliance A031501). Presented at the ASCO Annual Meeting. May 29 - June 2, 2026. Chicago, Illinois. Abstract 4513.
